SourceOne Stock Info  Your one source site for stock research




Company Website

Investor Relations



What’s the buzz—

message boards


Market Watch

Money Central

Raging Bull

Board Central









Biogen Idec Inc



Biogen Idec Inc. is engaged in the research, development, manufacturing and commercialization of therapies. Biogen Idec has five products: AVONEX, RITUXAN and ZEVALIN, TYSABRI and AMEVIVE. AVONEX is for the treatment of relapsing forms of multiple sclerosis. RITUXAN and ZEVALIN are for the treatment of certain B-cell non-Hodgkin's lymphomas. TYSABRI, formerly known as ANTEGREN, is approved by the United States Food and Drug Administration (FDA) to treat relapsing forms of MS to reduce the frequency of clinical relapses. AMEVIVE is approved in the United States for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.


Stock Quotes and Other Information





Silicon Investor



Market Watch

Clear Station



SourceOne Message Board


Search for Stocks:

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Alphabetical Listings by Company Name
















S&P 100     S&P 500     S&P 400     Dow Jones Industrials     Dow Jones Transportation     Dow Jones Utilities     Dow Jones Composite     Nasdaq 100     Morgan Stanley Hi-Tech 35